Featured Research

from universities, journals, and other organizations

Female hormones key to breast, ovarian cancer in BRCA gene carriers

Date:
October 16, 2013
Source:
University College London - UCL
Summary:
Researchers announced today that they are well on the way to discovering why women with the faulty genes BRCA 1 and BRCA 2, one of which was inherited by the actress Angelina Jolie, develop breast and ovarian cancer rather than other cancers.

Breast cancer cells.
Credit: Annie Cavanagh, Wellcome Images

Researchers announced in the journal Lancet Oncology that they are well on the way to discovering why women with the faulty genes BRCA 1 and BRCA 2, one of which was inherited by the actress Angelina Jolie, develop breast and ovarian cancer rather than other cancers.

Related Articles


The study, carried out by researchers at the UCL Department of Women's Cancer, found that abnormal levels of female hormones in the bloodstream could be the answer. The findings have already led to more research into novel ways of preventing cancers in women at risk.

According to the results of the study, women with BRCA1 or BRCA2 mutations are exposed to different levels of the female hormones oestradiol and progesterone, which are already known to be risk-factors for breast and ovarian cancer.

The findings indicate that BRCA carriers have abnormal hormone regulation, possibly due to a mechanism linked to the altered BRCA genes in carriers' ovaries. It is also possible that BRCA gene alterations change the sensitivity of tissues to hormones. More research into these mechanisms is needed.

The findings open up a new window of opportunity to prevent breast and ovarian cancer in BRCA mutation carriers. The authors anticipate that following further lab work, an existing drug -- currently used to treat osteoporosis -- could be suitable for use in a clinical trial of breast cancer prevention in BRCA1/2 carriers.

Professor Martin Widschwendter, Head of the UCL Women's Cancer Department who led the research said: "We have shown for the first time that cancer risk in BRCA1 and BRCA2 carriers is not just caused by local defects in the ability of cells to repair themselves."

He added: "An additional, systemic problem -- abnormal levels of female hormones in the bloodstream and altered downstream effects -- is the likely explanation as to why BRCA1/2 mutations carriers develop breast and ovarian cancer rather than other cancers."

In the study, researchers analysed 1966 uterus lining thickness measurements, taken using ultrasound scans. They compared 1573 measurements in women negative for both mutations with 203 measurements from carriers of BRCA1 and 190 with BRCA2.

Because the thickness of the uterus lining, or endometrium, is known to depend at least partly on the levels of female hormones, researchers then measured the concentration of these hormones in the participants' bloodstreams.

Not only did they find that carriers of BRCA1/2 did have higher concentrations of female hormones, they also found that differences in the levels of hormones correlated with the differences in the thickness of the endometrium in the second half of the menstrual cycle.

Based on these findings, research has already begun into how estrogens affect the Fallopian tubes, as this is where the majority of "ovarian" cancers in BRCA1/2 carriers actually start. The goal is to design drugs that might prevent the carcinogenic effect of high concentrations of estrogens in the Fallopian tube.

The other female hormone, progesterone, is known to trigger molecular changes in breast cells, specifically the production of the growth factor protein RANKL, which lead to cancer. Blocking and neutralizing RANKL by applying an antibody is an entire new concept to prevent breast cancer and will be tested in women with BCRCA1/2 mutations by Prof Widschwendter's team after further laboratory work.

Dr Adam Rosenthal, also from the UCL Department of Women's Cancer and one of the study co-authors, said: "Many women with BRCA1 or BRCA2 mutations decide to have their breasts and ovaries removed because of their high-risk status. Clearly this is a drastic measure and there is an urgent need to develop less extreme approaches for cancer prevention in such women."

Helena Morrisey, chairman of The Eve Appeal is delighted with the news. "We are proud to have funded this research which is a fantastic step towards our ultimate goal of prevention of women's cancer. We are hopeful that based on this study and future work funded by the Eve Appeal, women at high risk won't have to go through what Angelina Jolie went through."


Story Source:

The above story is based on materials provided by University College London - UCL. Note: Materials may be edited for content and length.


Journal Reference:

  1. Martin Widschwendter, Adam N Rosenthal, Sue Philpott, Ivana Rizzuto, Lindsay Fraser, Jane Hayward, Maria P Intermaggio, Christopher K Edlund, Susan J Ramus, Simon A Gayther, Louis Dubeau, Evangelia Ourania Fourkala, Alexey Zaikin, Usha Menon, Ian J Jacobs. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. The Lancet Oncology, 2013; DOI: 10.1016/S1470-2045(13)70448-0

Cite This Page:

University College London - UCL. "Female hormones key to breast, ovarian cancer in BRCA gene carriers." ScienceDaily. ScienceDaily, 16 October 2013. <www.sciencedaily.com/releases/2013/10/131016212603.htm>.
University College London - UCL. (2013, October 16). Female hormones key to breast, ovarian cancer in BRCA gene carriers. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2013/10/131016212603.htm
University College London - UCL. "Female hormones key to breast, ovarian cancer in BRCA gene carriers." ScienceDaily. www.sciencedaily.com/releases/2013/10/131016212603.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins